stent periférny zilver ptx ziv6-35 / ptx-set ziv6-35 / ptx zisv6-35
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
systém biliárneho stentu evolution
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
systém duodenálneho stentu evolution
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
systém ezofageálneho stentu evolution
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
systém kolonického stentu evolution
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
kliešte bioptické zozadu zakladané bigopsy
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
sada a podnos na perkutánnu tracheostómiu blue rhino g2-multi percutaneous
cook ireland ltd. o´halloran road, national technology park limerick Írsko -
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcie syncytiálneho vírusu dýchacích ciest - vakcíny - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.
firmagon
ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
jevtana
sanofi winthrop industrie - cabazitaxel - prostatické nádory - antineoplastické činidlá - jevtana v kombinácii s prednizónom alebo prednizolónom je indikovaná na liečbu pacientov s metastatickým karcinómom prostaty refraktérneho pôvodu, ktorý bol predtým liecený režimom obsahujúcim docetaxel.